

(51) International Patent Classification ⁷ :

A61B 3/12

A1

(11) International Publication Number:

WO 00/47107

(43) International Publication Date:

17 August 2000 (17.08.00)

(21) International Application Number: PCT/IB00/00274

(22) International Filing Date: 15 February 2000 (15.02.00)

(30) Priority Data:

9903394.6

15 February 1999 (15.02.99)

GB

(71) Applicant (for all designated States except US): AVIMO GROUP LIMITED [SG/SG]; 34 Bukit Pasoh Road, Singapore 08948 (SG).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PANG, Kian Tiong [SG/SG]; Avimo Electro-Optics Limited, 14 Fifth Lokyang Road, Jurong Town, Singapore 629763 (SG).

(74) Agents: SCHLICH, George, W. et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).


(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHOD AND APPARATUS FOR TREATING NEOVASCULARIZATION



(57) Abstract

A method and apparatus for detecting and treating diseases of a type associated with the growth of new blood vessels (neovascularization) in choroidal or subretinal layers of the eye and which can be used for more accurately locating a feeder vessel to the neovascularization and for blocking such a feeder vessel by photocoagulation with a laser.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHOD AND APPARATUS FOR TREATING NEOVASCULARIZATION

The present invention relates to a method and apparatus for
5 detecting and treating diseases of a type associated with
the growth of new blood vessels (neovascularization) in
choroidal or subretinal layers of the eye. More
particularly, the invention can be used for more accurately
locating a feeder vessel to the neovascularization and for
10 blocking such a feeder vessel by photocoagulation with a
laser.

Age-related Macular Degeneration (AMD) is a chronic disease
affecting primarily the choriocapillaris, Bruch's membrane
15 and the Retinal Pigment Epithelium (RPE). It is the most
common cause of legal, irreversible blindness in patients
aged 65 and over in the US, Canada, England, Wales,
Scotland and Australia. Although the average age of
patients when they lose central vision in their first eye
20 is 65 years, some patients develop evidence of the disease
in their fourth or fifth decade of life.

Approximately 10% to 15% of patients manifest the exudative
form of the disease. Exudative AMD accounted for 79% of
25 legally blind eyes. The disease is bilateral with
accumulating chances of approximately 10% to 15% per annum
of developing the blinding disorder in the fellow eye. The
recurrence rate of a treated neo-vascular membrane has been
estimated to be 50% within 18 months, but more recent
30 research with Photo-Dynamic Therapy (PDT) has indicated a
recurrence rate of 50% within 12 weeks from the last
treatment.

The hallmark of the exudative form of the disease is a
35 Choroidal Neo-Vascular Membrane (CNVM) that grows beneath
the retina or the RPE in the foveal-macular region. This
CNVM leaks and bleeds evoking a scarring reaction that

eventually results in the scaring of the affected area with consequential blindness. Histopathology of these CNVMs revealed that the vast majority of the membranes are nourished by a few (1 to 3) feeder vessels only. This means that only a few "vascular bridges" connect the origin of the CNVM (in the choroid) to the new location beneath the retina or the RPE.

The currently available treatment, as recommended by the Macular Photocoagulation Study (MPS) is massive destruction of the membrane with an appropriate laser. Unfortunately, most of the membranes are sub-foveal when discovered and such a treatment modality leads to the complete destruction of all tissues - CNVM and retinal - within the treated area. It has been suggested that focusing on feeder vessel destruction will minimise the collateral damage caused by massive tissue ablation. The major problem with this feeder treatment is the limited patient eligibility because of the difficulty in identifying feeder vessels. (Ref: F Shiraga, et al. OPHTHALMOLOGY, 105#4, 662-669, Apr 1998.)

Thus existing techniques for the treatment of AMD can not treat the disease satisfactorily. The known techniques routinely damage blood vessels and tissues unrelated to the disease or the disease-causing areas. Essentially, these techniques lack the ability to locate and destroy feeder vessels to the neovascularization with sufficient accuracy.

One object of the present invention to provide a method of treatment of neovascularization that overcomes or at least ameliorates the disadvantages identified.

Another object of the present invention to provide apparatus which can be used for more accurate determination of the location of feeder vessels to the neovascularization.

Accordingly, a first aspect of the invention provides a method of treating neovascularization in the eye of patient comprising:-

- 5 (i) introducing a detectable marker into the circulation of the patient at a point remote from the eye;
(ii) observing a region of suspected neovascularization in the eye after introducing the marker;
(iii) detecting the location of the onset of the marker
10 into the region in order to determine the location of a feeder vessel to the region of neovascularization or an anomaly in the retinal pigment epithelium; and
(iv) photocoagulating the feeder vessel to prevent it from feeding blood to the neovascularization.

15

The invention also provides apparatus for examination of neovascularization in an eye of a patient, comprising:-

- a light source for exciting a dye introduced into the
20 circulation of the patient;
an image generator for generating an image of a region of the eye under examination; and
an image recorder for recording a plurality of images of the region.

25

- WO-A-98/46122 describes one form of apparatus which, together with the modifications and/or improvements described herein, can be used in preferred embodiments of the invention. Where applicable, the contents of
30 WO-A-98/46122 are incorporated herein by reference.

- Typically, the detectable marker is a fluorescent dye, the region is illuminated by radiation that excites the dye and the first appearance of the dye in the region is detected
35 as an increase in brightness by a predetermined amount above background levels. In an example of the invention in use, a video image of the region is monitored for the first

appearance of the dye. Initially, the image is dark, indicating that no fluorescent dye has entered a blood vessel contributing to the image. As soon as the dye does enter the field of the image, it is visible as an area of increased brightness and its position and course is readily seen and recorded.

As the time between the first appearance of the marker with just one or a small number of areas of brightness in the image and the filling of most of the image with the dye is usually very short, of the order of fractions of a second, it is preferred that the region is observed by recording a succession of images of the region using an image recorder and subsequently examining the recorded images to identify the location of a blood vessel feeding blood into the region. This enables images to be stored for later examination. A suitable rate of capture of images is at least 30 per second, though it is preferred that the rate is at least 45 per second, and higher rates such as 60 per second and greater will tend to give improved identification of feeder blood vessel location.

In an embodiment of the invention, the recording of images of the region is triggered by triggering means associated with the image recorder and sensitive to an increase of the marker in the region. The trigger can be set so as to trigger image capture when the brightness level rises above the average background level plus a predetermined amount. This may be initially set at a level of, say, 10 per cent but is usually optimised empirically. Computer memory usage for image storage is relatively high, and thus this embodiment is of benefit in that unnecessary storage of image prior to the first appearance of the dye in the region is reduced and may even be totally avoided.

35

In an alternative embodiment of the invention, the recording of images of the region is immediately initiated

at the injection of the marker(s). In this embodiment, the total recording time must be of ample length so as to record the earliest appearance of the marker in the region (and even into later periods when the marker accumulates and fills in the region). The total recording time should preferably be 30 seconds or more for storing images at a rate of 30 full frames per second, minimum. It is even more preferable to have a total recording time of 30 seconds or more for storing images at a rate of 60 full frames per second or more. In this embodiment, no triggering or empirically determined threshold is required as ample recording media (memory) is provided to store the entire captured sequence of images. Thus, no particular sensitiveness to the increase of the marker is required.

In a further embodiment of the invention, the method additionally comprises introducing a second detectable marker into the circulation of the patient, and detecting the location of the second detectable marker in the region so as to determine the position of the blood vessel walls in the region. This second marker is generally used to identify blood vessels throughout the region, so as to build up a map or network of the vasculature especially the blood vessel walls of the feeder vessels suspected of causing or contributing to the disease. This second detectable marker can be used in real time, not needing the fast image capture of the first marker. In use, the image or images showing the location of the first appearance of the first detectable marker into the region are compared with the position of the blood vessel walls located by the second detectable marker, such as by overlaying one image onto the other, so that it is possible to determine the location of a blood vessel feeding blood into the region. This introduces further accuracy into the identification of the feeders, or, a confirmation of the locations of suspected feeder blood vessels. For example, if the CNVM is under examination, the stained blood vessel walls can be

compared with the positions of the first fillings of the region and only those overlapping areas are to be considered as feeder vessels to be treated.

- 5 The treatment to be applied may be by conventional laser photocoagulation. In addition, it is a preferred embodiment of the invention that the treatment is carried out using a laser having the same absorption wave band of the second detectable marker.

10

In apparatus embodying the invention, an image generator generates an image of a region of the eye under examination; and an image recorder records a plurality of image frames of the region. The image recorder preferably
15 records images at a rate of at least 30 frames per second, or faster, and for a total recording time of not less than 30 seconds (at whichever rate being used).

20

In a preferred embodiment of the invention, the apparatus the further comprises a trigger means associated with the image recorder and sensitive to an increase of the marker in the region, wherein it triggers image recording in response to an increase of the marker in the region above a predetermined level.

25

Thus using the method of the invention, in order to locate a target, it is not necessary to see the target clearly or sharply, as long as the target is marked or contrasted or is easily differentiated from the background by a visible
30 marker, e.g. a dye.

Embodiments of the invention will now be described with reference to the accompanying drawings in which:

- 35 Fig.1 is a schematic diagram of ophthalmological apparatus for examining and treating the eye.

Figs.2 and 3 schematically illustrate parts of the eye.

Figs.4a-4c and 5a-5e show image frame sequences and the spread of a marker into a feeder region of a neovascularization:

Referring first to Fig.2, this shows schematically a section through the eye and illustrates the lens 1 of the pupil region, the schlera 2, and retina 3. The section also shows the choroid 4, pigment epithelium 5 and fovea 6. Referring next to Figs. 3a-3b, these schematically illustrate a magnified portion of the eye including the RPE (retinal pigment epithelium) 5, shown as a layer. Figs. 3a-3b are shown as a sequence to illustrate the anatomy and growth of the CNVM (choroidal neo-vascular membrane). This includes the RPE, which is furthest from the cornea, protruding feeders and the CNVM itself which grows into the retina or pushes the RPE upwards causing a "bump" in the retina (as depicted by the sequence of Figs. 3a-3b). The invention enables the location of a feeder 7 to the neovascularization to be more accurately determined (compared with the techniques described in WO-A-98/46122). For example, after introducing a marker into the patient's circulatory system, the marker can be detected in the foveal-macular region of the patient's eye when it starts to fill the feeder, whereby the location of the feeder 7 to the neovascularization can be accurately determined so that a laser can be subsequently used to cause photocoagulation, thereby blocking the feeder. In carrying out this method, a high speed CCD camera is coupled to an image intensifier which in turn is coupled to the optical system that is focused on a region where a feeder 7 is suspected. Whilst this does not essentially require confocal paths, they would be useful for focusing on a thin slice. For example, if such a slice were thinner than the gap between the choroid or RPE and the CNVM, the optical system can be focused on feeders suspected to be located somewhere

between the top and bottom of the "bump", while the RPE and CNVM would remain out of focus, i.e. blurred out. However, the confocal system is not essential in every case. The choroid cannot be seen because it is shielded by the RPE (which is opaque to visible light) and to see the choroidal vasculature, ICG (in the IR) and the confocal capability to focus above the choriocapillaris can be employed to detect the lesion protruding into the RPE, the marker being a substance such as fluorescein (in the visible blue/green).

5

10 Whilst fluorescein filling of the choroid is not visible (because of the RPE), unless there are breaks in the RPE (due to the feeders/CNVM of a disease, or just "window defects", feeder filling will be seen followed by the neo-vascular network filling, by observing bright spots against a dark RPE background. i.e. with focus on or about the RPE/retina. This is schematically illustrated by the sequence Figs. 4a-4c, which show respectively the start of the filling of the feeder and the subsequent filling of vessels by capturing frames of image information with the high speed camera. Almost immediately after the appearance of bright spots indicating the locations of feeders, the visible retinal vasculature fills, producing a brilliant flash which drowns out all the spots. By careful selection and adjustment of timing, i.e. to ensure that sufficient image frames are captured at a high enough frame speed, the captured frames show the first appearance and subsequent growth of these spots. These frames (of interest) which are taken over a very short period of time, can be subsequently examined and analysed to see how the brightness of each spot develops (between the choroidal filling and the retinal flash). Confocal paths are of use because they enable narrow focusing on a layer just above the RPE and not too much into the retina. In this way, the retinal flash can be reduced or eliminated (i.e. noise reduction/elimination. Then ICG and the confocal system (if needed) can be used to confirm that these spots are diseased (and not window defects in the RPE). Disease

15

20

25

30

35

spots are stained by ICG in the longer term (e.g. of 3-5 minutes post-injection). By then superimposing flourescein stills on the live, evolving ICG staining, and focusing on the thin layer about the spot (so as not to excite the ICG, which may still be coursing through the normal choroidal and retinal vasculature - but which would be out of focus in the confocal system), the disease spots can be confirmed, targeted and treated.

Fast cameras and fast computers can be used to catch those images between the invisible filling of the choroid and the invisible filling of the retinal vessels. There is no need for specific focusing at locations where feeders are suspected to exist. It would help in signal discrimination, especially with confocal paths, but is not necessary if frames can be captured in the intervening few milliseconds between sequential fillings. Hence, one would see dark, a few brightening spots and then the flash of the retinal vessels. Referring to Fig. 1, this schematically illustrates the kind of apparatus which can be used to carry out the invention. Reference is also made to WO-A-98/46122, for further details of the optical and other systems which are represented schematically in Fig. 1 by the main body 11, which includes inter alia the magnifying objectives 12. Fig. 1 shows the eye 10 positioned in front of the lens system and further details of this will be apparent from WO98/46122. Arranged on the image path is an image intensifier 13 coupled to high speed CCD camera 14. This is linked to video image generating apparatus including a TV unit 15, CCR 16 and image converter 17. Monitor 15a enables images to be viewed. Camera 14 also has a input for a frame grabber 18 which is linked to computer 19. Motion control unit 20 is coupled between the main body 11 and computer 19. An XYZ control panel 21 is coupled to translation (XYZ) stages 22 also coupled to the main body 11. A laser photocoagulator 23 is connected by means of a fibre optic light guide to the magnifying

objective lens system 12. A visible illumination source 24b and a near IR illumination source 24c are on an illumination path 24d to a filter system 24a which is coupled to the magnifying objectives 12.

5

Essentially, the system disclosed in WO-A-98/46122 is upgraded with more speed, more RAM, and image capturing means which enable images to be captured in the required brief time interval and with the necessary spatial resolution, so that the feeders can be identified and treated.

10

The distribution of the marker inside the target region, such as within a CNVM, always starts at the feeder or feeders. Consequently, the more closely temporally-spaced images are captured during the first second of the marker's entry into the CNVM, the better the chances of locating and confirming the feeders. That is, each image should be captured in as short a period as possible (i.e. high temporal resolution), and, the time elapsed between consecutively captured images should be as short as possible (i.e. high rate of capture). In addition, each image should have as high an image resolution as achievable so that details of the region can be seen. The invention may use any high speed image -capturing devices or sensors currently available to achieve improved identification of the feeder vessels.

15

20

25

30

Where triggering and threshold detection are not required, a feeder can be identified and located by the following technique.

35

- (i) The entire captured sequence can be replayed in "slow-motion-stop- frame" so that the few (consecutive) images in which the marker first appears can be identified.
- (ii) The brightening regions (or spots) in one of these images can be defined (marked out) and "registered".
- (iii) A graph plotting the brightness levels (within each of the registered spots in every image in the captured

sequence) against the order of the images (in the captured sequence).

(iv) In this manner, the brightness changes (increases) with time, within each registered spot, from before the marker arrives to well after the marker has filled the spots, can be illustrated graphically. Any suitable type of graphs can be used: 2-dimensional, 3-dimensional, histogram, etc.

(v) The rise and fall of the graph of each registered spot identifies a spot as a suspected feeder, or a "window defect" in the RPE. A feeder will fill with the marker and maintain its saturated brightness. A break (in the RPE) will show the underlying flash followed by a reduction in the brightness over several seconds (hundreds of images) before the brightness level rises again in the redistribution of the bolus. Hence, feeder locations are identified.

(vi) Other anomalies (in the RPE) can be studied by this method.

20

It has been found that magnification is more important than resolution when searching for a feeder vessel. In preferred embodiments of the invention, an operator may trade off a decision not to pursue higher resolution to enable a better view of a feeder. Preferably, accurate destruction of the feeders should be performed immediately once they are identified, and the invention advantageously provides for these functions both to be incorporated in one instrument.

30 In a specific embodiment of the invention, two fluorescent dyes, ICG and fluorescein, are injected into the circulation (simultaneously or separately) as is done in any current angiographic imaging procedure. At the earliest entrance of the fluorescein into the choroidal circulation, 35 the increase in the brightness of the background haze is detected by the instrument, which then automatically self-triggers the image acquisition. The very earliest

filling of the CNVM is acquired as rapidly as possible using a (digital) camera operating at a rate of 60 frames per second. The faster the image acquisition, the better the details of the earliest appearance of the dye, the better the ability to locate and confirm feeder vessels. All the images acquired during this early phase are presented on the computer monitor to be studied by the instrument operator(s). The earliest images that show the entry of the fluorescein into the CNVM are isolated and selectively stored as individual frames (marked or numbered or both) in the computer memory.

Image processing (software) is then used to analyse and enhance the location(s) where the fluorescein starts its entry into the CNVM. While executing this procedure of analysing fluorescein early filling, the second marker, ICG, is staining the vessel walls of the CNVM. This staining process is being monitored, in real time, by the instrument operator(s). The stored image(s) of the first (fluorescein) marker's early filling is recalled, made semi-transparent and then overlaid or otherwise superimposed on the real-time image of the ongoing staining of the membrane by the second marker. Only the stained vessels of the CNVM that are within the marked areas of the stored early (fluorescein) filling images are to be considered as possible feeders. A (100(m laser spot of appropriate power is aimed directly at the suspected feeder(s) and the treatment mode (photocoagulation) is executed. Preferably, the laser spot size should be between (50(m and (100(m to adjust to the expected cross-sections of the feeder vessels. Even more preferably, the laser spot size itself may be adjusted, in real time, by any combinations of optical and opto-mechanical means, between these limits. An aiming beam enables accurate laser shots to be applied to the target(s).

The wavebands of the treatment laser used for the treatment

and the aiming are the same as that needed to excite the fluorescent marker (ICG) that stains the vessel walls of the CNVM. In this way, it is possible to combine better targeting and better treatment at lower powers due to
5 enhancement in the absorption (of laser energy) by the second marker.

The instrument itself may also include a self-tracking system that uses the large vessels at the rim of the optic
10 disc as alignment reference points in order to overcome the patient's unintentional eye movements.

The method of the invention is found to produce good results as it enables high magnification of the CNVM (while
15 compromising on resolution). This "trade-off" is possible in the embodiments of the invention because the targets are marked with fluorescent markers.

The overlaying of the locations of early filling obtained
20 by the first marker on the real-time image showing the staining of the CNVM walls by the second marker enables identification and confirmation of the feeder vessels that contribute to the disease. These specific vessels may then be considered for laser photocoagulation treatment without
25 the massive destruction of areas of healthy vasculature and tissue.

The use of a laser that emits in the same waveband as the excitation waveband of the marker that stains the vessel
30 walls confers the further benefit of less collateral damage due to the lower laser power needed to block the stained vessels.

The "self-tracking" embodiments of the invention can be
35 likened to computerised finger-print recognition, at a basic level. It may be achieved using the following steps. The computer remembers a "map" (image) with key

(user-registered) landmarks. Upon receiving a new image (live or still), it uses that (stored) map, rotates it, scales it, or uses any (known) means to find out if the new image is the same as the map but in a different orientation and/or scale. The "self-tracking" function has 2 parts:

5 (i) once the first (map) image is registered (in the memory) with its landmarks (e.g. where major vessels emanate from the edge of the optic disc), the software must find the same location every time (and maybe, be able to

10 move the machine to the re-oriented map position), and,

(ii) if required to zoom in on a specific area within the new image (i.e. re-scale the new image), the software must triangulate (based on the landmarks) and memorise the co-ordinates so as to zoom in, (and maybe later, zoom out

15 to the scale of previous image). It must also keep the machine pointed at the same spot during any operations.

Below are the descriptions of specific embodiments of the invention to illustrate the invention in a non-limiting way.

20

EXAMPLE 1 - Using Threshold Triggering

A flow chart of a method of the invention is thus:-

25

S1: Main Start

(

S2: Fluorescein Sequence

(

30

S3: ICG Sequence

(

S4: Treatment Sequence

(

S5: PDT Sequence

35

In more detail, a method of the invention is carried out as follows.

MAIN START - S1

The patient is prepared :

Measure the curvature of the cornea for the best-fitting
(or the closest-fitting) contact lens to use.

5

Dilate the pupil, insert the lid retractor, etc.

Adjust the fixation light, the head-chin rest and the seat
height to pose the patient in an appropriate and comfortable.

10

Insert an intravenous tap (through which the dyes can be
injected) usually at the back of one hand.

FLUORESCEIN SEQUENCE - After completing S1

15

Use "general illumination" (any colour) to aim at the
appropriate area, adjusting the illumination intensity, the
magnification and the focus (in any order) to achieve the
required field of view and details. (Illumination is
adjusted to the appropriate minimum levels such that clear,
20 low-noise images can be seen, i.e. no exact magnitude can
be stated as it depends on the optics and media of the
machine and the human eye. The images are black and white,
using grey level determination.)

25

Usually, use low magnification (and therefore wider field)
to begin.

Once the general (or specific area) is in focus, change the
filters to the appropriate set (blue excitation,
30 (=480-495nm; green barrier, (=515-535nm) for fluorescein.

Prepare triggering software :

Preset to capture images at the maximum frame rate (60 full
frames per second because of the blood flow rate - it takes
35 10-25s after injection for the dye to arrive in the eye)
for the maximum length of time permissible. (The latter is
limited by the size of the computer memory).

Take a background scan of the image using the chosen filter set. The image is black (if no fluorescein is present) as the barrier filter does not pass the blue excitation illumination.

5

Set the triggering threshold to be the background level plus xx units. (xx is empirically established or estimated. The units are usually grey levels. The threshold is usually the average brightness of the entire image or the diagonal strips of pixels across the image, etc - depending on the speed of the computer, the CPU time allowed for the averaging operations, etc. Or, any other sensitive measure of brightness changes in an image.) Hence, the threshold is relative to the "background" (brightness) plus xx. It does not matter if the dye is already present; only the increase in the signal (above the earlier recorded "background") is needed threshold triggering. (See Comments below for an alternative to threshold - triggering.)

10

15

20

Inject 3-4ml (or an appropriate dose) of fluorescein through intravenous tap.

25

30

On the earliest appearance of the fluorescein in the field of view (FoV - i.e. the focal plane), and at an image brightness equal to or greater than the threshold, the evolving filling of the vessels in the FoV is captured and stored in the computer memory. Only a few (consecutive) frames (<10), when the fluorescein signal begins to appear and increase (in the vessels) are useful. The brightening spots in these few frames suggest the location(s) of the feeder vessels because (they are filled first). The rest of each of these few frames should remain darker (as they are yet to be filled at this time).

35

The fluorescein filling begins in the choroid (below the retina). However, the Retinal Pigment Epithelium (RPE - the pigmented layer between the choroid and the retina) blocks (or strongly and significantly attenuates) the excitation

illumination from reaching the choroid. The RPE also blocks the fluorescein fluorescence (if any) from the choroid. The feeders breach the RPE to feed the associated membranes in the sub-retina. These feeders (followed by the membranes) will fill after choroid filling but before the retinal vessels flash. The time lapse between choroidal and retinal filling is (usually) less than 100 milliseconds. Hence, expect a darkened image, then a sudden bright flash (as retina vessels fill). (In contrast, the eye blink response is estimated to be about 250ms.)

If the triggering sequence is correctly captured, either of the following is expected:-
spots or lines indicating where the feeders fill, followed by a spreading (fanning) out of the filling into patches in the immediate neighbourhood of the spots or lines (feeder vessels), or,
spots and lines fill, followed by a spreading out of the filling, centred about the spots and lines, until the spots and lines disappear in the brightening patches.

Thus, the first few consecutive frames capture the locations of the first filling of the spots and lines that are the suspected feeders. After that, the capillaries-membranes fill - overwhelming the feeder locations or not - then the retinal vasculature begins to fill and the entire image is overwhelmed by a bright flash.

The captured sequence is displayed for the operator to inspect in order to locate the suspected feeder(s) - the spots and lines.

These first few (<10) frames are (image-processed to increase image clarity, if needed, and) stored in permanent memory (hard disk). The entire captured sequence can also be saved, as required; e.g. for demonstration purposes.

Repeat the injection and image-capture sequence, if the previous sequence is unsatisfactory. Use another 2-3ml of fluorescein. Note that the already present fluorescein will contribute to the higher background "noise".

5

ICG SEQUENCE - After completing S1 and S2

Revert to "general illumination" and adjust the intensity, the focus and the magnification on the suspect area(s) - those determined by fluorescein early filling.

10

Change to the ICG filter set; change the illumination to infra-red (IR: (=780-790nm); barrier ((=810-880nm)).

15

Adjust the IR illumination intensity - usually low; depends on the optics, the media and the amount of ICG to be injected.

20

ICG early filling is unlike the patchy fluorescein filling. Captured images have higher contrast, showing the sequential filling from the choroidal to the (arterial) inflow, to the fine filling of the capillaries-membranes and to the (venous) outflow of the feeders, and lastly, to the retinal vasculature. This allows for a 2-dimensional - or a 3-dimensional reconstruction of the sequentially captured images to visualise the structure - direction of vessel growth, etc - of the feeders and the capillaries-membranes.

25

Variation A

30

Run the software (as before for fluorescein).

Capture an ICG early filling sequence for comparison to the fluorescein sequence to confirm the location(s) of the feeders.

35

Inject 2-3ml of ICG (through the intravenous tap).

Capture the ICG early filling (as before for fluorescein). The image is black before ICG arrival. When the ICG arrives, there will be choroidal flash, followed by the filling of the feeders, (spreading out from arterial to venous), and lastly, the retinal filling.

Store the captured sequence or frames as required (as in Fluorescein Sequence).

10 Variation B

Select one or a few frames from the stored, early -fluorescein -filling.

Overlay the selected frame(s) on the "live" image (at the same magnification, orientation, etc). (See "self-tracking".)

Inject 2-3ml of ICG (through the intravenous tap).

20 Observe the ICG filling and the staining of vessels under the superimposed (fluorescein frame).

Variation C

Inject 2-3ml of ICG (through the intravenous tap).

25

Observe and directly capture (no need to use the trigger-capture) the inflow and the outflow of ICG through the (particular area of the) circulation - the filling from the arterial to the venous sides of the feeder and the membranes. Can It is possible to see where and how the ICG bolus moves through the circulation - thereby locating the feeder (arterial) input into the membrane.

35 The ICG fills the vessels, then is removed from the circulation. However, the ICG stains the diseased vessels (feeders) so that as time elapses, only the ICG-stained feeders will remain visible. Therefore, by adjusting the

illumination intensity accordingly, the non-pathological circulation will fade out of view (in about 3-5 minutes post-injection).

5 Feeder locations are thus confirmed.

Maintain the same filter set, adjusting IR illumination as needed.

10 TREATMENT SEQUENCE - After completing S1, S2 and S3
Move the treatment laser aiming beam ($\lambda=633\text{nm}$) to the location of the feeder(s) - the ICG-stained spots (usually arterial first, if they can be differentiated).

15 Adjust the treatment power and the pulse duration.
(Magnitudes are empirically established or estimated.)
Usually, start at a lower power-duration combination, then increase until the required effect is seen on the live image. (Usually no more than 1000mW for up to 300ms per pulse is used.)
20 Alternatively, fix the power-duration combination but repeat the pulsing until the required effect is seen. (The number of pulses is not fixed.)

A small amount (1-2ml) of ICG can be simultaneously
25 injected (to increase the signal and the laser absorption).

Fire the treatment laser on the targeted feeder (until the required effect is seen, if possible). The treatment ($\lambda=810\text{nm}$) laser delivers thermal (IR) energy to the target.
30 It literally burns the feeders. Hence, it is important that the treatment spot be very concentrated ($<100\mu\text{m}$) to deliver a high concentration of thermal energy and to ensure that collateral damage - damage to the neighbouring areas about and beyond the laser spot - is minimised, i.e.
35 only the feeder is burned.

Inject a small amount (1-2ml) of ICG to look for immediate

confirmation of the treatment effect. If the treatment is effective, the feeder is blocked and the membrane does not fill (with ICG).

- 5 Depending on the FoV, the sequence may be repeated at other areas. (See "self-tracking".)

PHOTO-DYNAMIC THERAPY

- 10 A sequence similar in procedure to Photo-Dynamic Therapy (PDT) can be inserted at the end of the Treatment Sequence.

15 PDT uses the photo-chemical effect of a photo-sensitizer chemical which concentrates or is selectively absorbed in the pathological neo-vascular vessels. The photo-sensitizer does not stain or only minimally concentrates in healthy areas. The stained pathological areas are exposed to the sensitizer's waveband at low intensities for extended
20 periods. On activation (by the illumination), the photo-sensitizer releases singlet oxygen and/or other highly reactive intermediates ("free radicals") which can cause cellular damage in (the cell membranes of) the pathological new-growth vessels, which may result in
25 thrombosis of the vessels. It has been found that PDT may be more efficaciously applied on capillaries (in the membranes) than on the feeders (nourishing the membranes). It has been observed that the capillaries regrow within 12 weeks of the last PDT treatment. (U Schmidt-Erfurth,
30 ARCHIVE of OPHTHALMOLOGY, 117#9, 1177-1187, September 1999.) I broke into a new paragraph.

ICG can be analogously considered as such a
photo-sensitizer in our application. The principal
35 difference is that ICG does not release "free radicals" or such. It operates with low a purely thermal effect. Like PDT, the ICG is similarly exposed to power irradiation (

<50mW, for example). The value is not exactly known (depending on the staining, the optics and the ocular media).

5 The ICG excitation IR illumination is close to or can be the same as the treatment laser wavelength (or waveband). (This is because the overlap of ICG excitation and ICG fluorescence wavebands is relatively large. Each waveband, by itself, spans more than 100nm.) The difference between
10 illumination and treatment beams is that the continuous illumination is at much lower power and/or is much more diffused; while the treatment beam is much more focused (<100(m treatment beam spot) and at much higher pulsed powers (up to 2000mW).

15 ICG stains the capillaries in the membrane as well as the larger feeder-vessels. At low IR power, the feeders themselves cannot be photocoagulated. (Only the above-mentioned ICG and Treatment Sequences can destroy the
20 larger feeders). However, it may be possible to destroy the membrane capillaries using this long, low-power exposure on ICG. As such, the entire ICG and Treatment Sequences is, in effect, a PDT Sequence as well (even if the PDT Sequence detailed below is not used as part of the viewing and
25 treatment procedure outline in the flowchart above). This is because the continuous, diffused, low-power, ICG-excitation, IR illumination is always present in the ICG and the Treatment sequences. Hence, depending on the duration of the ICG and the Treatment Sequences, the
30 capillaries-membranes are in effect being treated as well. (The ICG and the Treatment Sequences are meant to locate and destroy the feeders only. Note that the feeder signals may be harder to extract in the presence of nearby or overlying membranes.)

35 If this is indeed the case, the patient may leave after this low-power exposure, i.e. the sequence may be

interrupted. After 1 to 2 weeks, the patient should be recalled for all the above sequences. If the PDT Sequence is successful, the capillaries, and therefore the membrane, do not accept (fluorescein and) ICG: they do not fill and no signal is emitted. However, the larger undamaged feeders will remain and will be stained and be fluorescent. The advantage of this is that the background noise is reduced (as the once-surrounding or overlying membrane does not fluoresce). The feeders are then more easily, more exactly located and more distinctly seen so that the Treatment Sequence can be more precisely applied.

In this manner, the capillaries-membranes are first destroyed as part of the procedure for locating the feeders. Then, the feeders are targeted and destroyed in the follow-up.

PDT SEQUENCE - After completing S1, S2, S3 and maybe, S4 Revert to "general illumination" and adjust the intensity, the focus and the magnification on suspect area(s) - those determined by fluorescein early filling images, or, broad areas without specific targets.

Change (or maintain) the filter set for ICG and infra-red illumination (IR: (=780-790nm).

Adjust the IR intensity slightly higher than before (but <50mW), depending on the optics, the media and the amount to ICG to be injected.

Inject (up to 10ml) of ICG, if needed, (determined by patient's body weight).

Expose the suspect area to IR for extended periods (>15 minutes). The exact exposure duration is unknown.

Variation A

The PDT Sequence can be carried out after executing the ICG and the Treatment Sequences because the diseased capillaries-membrane are not treated - too small or too fine, over too wide areas for the Treatment Sequence to be applied. Hence, apply the PDT Sequence after the feeder treatment to destroy the remaining capillaries-membranes.

Variation B

The PDT Sequence can be carried out before executing the Treatment Sequence, especially if the feeders cannot be clearly located because they are hidden by the overlying capillaries-membranes. In this case, apply the PDT Sequence to destroy the capillaries-membranes to reduce their "noise" contribution to the image so that the underlying feeders can be more clearly defined by a re-execution of the Fluorescein and the ICG Sequences (which may be carried out 1 or 2 weeks after the PDT Sequence).

EXAMPLE 2 - Using extensive RAM

Example 1 is repeated using very large (image) storage memory as an alternative to threshold triggering. Upon injection of any dye, the system immediately begins to capture and store all incoming images (at 60 frames per second or faster). With ample memory which provides the needed extended period of image capturing, the early filling is captured within 10-15s from injection. This takes care of false triggering due to over-sensitive threshold, or, no (or late) triggering due to overly high threshold setting (i.e. xx set too large). This setup has the added advantage of capturing any "anomalous" events before or after the first visual appearance of the dye. Note that the fast electronic sensor (CCD camera) can detect "brightness" increases that are still invisible to the human eye, or, that can be displayed (without enhancement) on the monitor screen. The user will, however, have to select those frames to be saved (on hard disk) as

saving the entire captured sequences will require too much memory (on the hard disk) and will also take too long to complete.

- 5 The invention thus provides methods for identifying and treating neovascularization such as in AMD.

Claims

1. A method of treating neovascularization in the eye of
5 patient comprising:-
introducing a detectable marker into the circulation of the
patient at a point remote from the eye;
observing a region of suspected
neovascularization in the eye after introducing
10 the marker;
detecting the location of the onset of the marker
into the region in order to determine the
location of a feeder vessel to the region of
neovascularization or an anomaly in the retinal
15 pigment epithelium; and
photocoagulating the feeder vessel to prevent it
from feeding blood to the neovascularization
2. A method according to Claim 1, wherein the marker is
20 a fluorescent dye, the region is illuminated by radiation
that excites the dye and the first appearance of the dye in
the region is detected as an increase in brightness by a
predetermined amount above background levels.
- 25 3. A method according to Claim 1 or 2, for treating
neovascularization in a Choroidal Neo-Vascular Membrane
(CNVM) in Age-related Macular Degeneration.
- 30 4. A method according to any of Claims 1 to 3, wherein
the region is observed by recording a succession of images
of the region using an image recorder and subsequently
examining the recorded images to identify the location of
a blood vessel feeding blood into the region.
- 35 5. A method according to Claim 4, wherein the image
recorder captures images at a rate of at least 30 per
second.

6. A method according to Claim 4 or 5, wherein recording of images of the region is triggered by trigger means associated with the image recorder and sensitive to an increase of the marker in the region.

5

7. A method according to any of Claims 1 to 6, wherein the blood vessel is treated by using a laser.

10

8. A method according to any of Claims 1 to 7, further comprising introducing a second detectable marker into the circulation of the patient, and detecting the location of the second detectable marker in the region so as to determine the positions of blood vessel walls in the region.

15

9. A method according to Claim 8, comprising comparing the location of the first appearance of the first detectable marker into the region with the position of the blood vessel walls located by the second detectable marker to determine and/or confirm the location of a blood vessel feeding blood into the region.

20

10. A method according to any of Claims 7 to 9, comprising treating the blood vessel using a laser wherein the waveband of the laser is the same as the absorption peak in the wave band of the second detectable marker.

25

11. A method according to any of the preceding claims, wherein a change in brightness is measured at the location of the onset of the marker and recorded against time to facilitate determining the locations of the earliest onset of the marker into the feeder vessel.

30

12. A method according to claim 11, wherein the change in brightness is recorded graphically.

35

13. A method according to claims 4-6 wherein an image (or

images) showing the earliest appearance (of the first marker) is made semi-transparent and then is superimposed on the real-time image in which the second marker is introduced, the presence of the second marker in underlying locations (in real-time) indicating and confirming the suspected feeder vessels; and absence of the second marker in underlying locations indicating and confirming that the suspected feeders have been coagulated successfully.

10 14. Apparatus for examination of neovascularization in an eye of a patient, comprising:-

a light source for exciting a dye introduced into the circulation of the patient;

15 an image generator for generating an image of a region of the eye under examination; and

an image recorder for recording a plurality of images of the region.

20 15. Apparatus according to Claim 14, wherein the image recorder can record images at a rate of at least 30 per second.

25 16. Apparatus according to either of claims Claim 14 or 15, further comprising trigger means associated with the image recorder and sensitive to an increase in the brightness of the marker in the region for triggering the image recorder to start recording when the brightness rises above a predetermined level.

30 17. Ophthalmological apparatus having a lens system for examining and treating the eye, whereby neovascularization can be diagnosed by introducing a marker into the circulatory system and detecting the marker in the foveal-macular region of the eye; the apparatus
35 comprising:

a laser source, an illumination source and an image intensifier arranged on respective optical

paths of the lens system;

a high speed CCD camera coupled to the image intensifier and to a video image generating system whereby frames of image information can be captured and stored in which the onset of the marker into a feeder vessel to the choroidal neo-vascular membrane (CNVM) can be detected, so that the laser source can be used to photocoagulate the feeder and thereby treat the neovascularization.

10

18. Apparatus according to claim 17, wherein the lens system includes confocal imaging paths.

15

19. Apparatus according to claim 17 or 18 including means responsive to an increase in brightness in an image generated in the frames so as to signal the arrival of the marker in the foveal-macular region of the eye so as to trigger the image generating system to begin recording frames at a frame rate fast enough to enable the onset of the marker in the feeder vessel to be determined, as well as subsequent filling of the feeder vessels, before the marker fills the visible retinal vasculature.

20

20. Apparatus according to any of claims 17- 19, wherein the marker is fluorescent and the light source emits radiation that excites the fluorescent marker.

25

21. Apparatus according to claim 20, wherein a second fluorescent marker is introduced into the circulation and including processing means programmed to detect the location of the second marker so as to determine the position of blood vessel walls so as to build up a map or network of the vasculature including feeder vessels, and to show an image or images of the location of the onset of the first marker against the images of the vasculature, to facilitate determining the location of the feeder vessel.

30

35





FIG. 2






FIG. 3a




FIG. 3b




FIG. 3c

FIG. 4a



FIG. 4b






FIG. 4c



a = ARTERIAL
v = VENOUS

FIG. 5



$$t = \frac{1}{60} \text{ s}$$

$$\frac{2}{60} \text{ s}$$

$$\frac{3}{60} \text{ s}$$

$$\frac{4}{60} \text{ s}$$

$$\frac{5}{60} \text{ s}$$



$$t = \frac{1}{60} \text{ s}$$

$$\frac{2}{60} \text{ s}$$

$$\frac{3}{60} \text{ s}$$

$$\frac{4}{60} \text{ s}$$

$$\frac{5}{60} \text{ s}$$

FIG. 5a

FIG. 5b

FIG. 5c

FIG. 5d

FIG. 5e

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 00/00274

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61B3/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61B A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 46122 A (AVIMO EUROP LIMITED; AVIMO GROUP LIMITED (SG); PANG KIAN TIONG (SG) 22 October 1998 (1998-10-22) cited in the application	14-20
A	page 37, line 3 - line 24 page 5, line 12 - page 6, line 9 page 7, line 19 - line 24 page 29, line 12 - line 28 ---	21
X	WO 96 18415 A (UNIV JOHNS HOPKINS) 20 June 1996 (1996-06-20)	14, 17, 20
A	page 19, line 16 - line 28 page 24, line 13 - line 26 page 26, line 10 - page 27, line 17 page 35, line 1 - line 16 ---	15, 21
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

26 June 2000

Date of mailing of the international search report

03/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Knüpling, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KLINGBELL U ET AL: "LASER-BASED FUNDUS CAMERA FOR INFRARED ANGIOGRAPHY" OPTICAL ENGINEERING, US, SOC. OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS. BELLINGHAM, vol. 34, no. 3, 1 March 1995 (1995-03-01), pages 737-745, XP000495218 ISSN: 0091-3286	14
A	section "2.2 Optical Systems" section "2.4 Digital imaging System" section "4.2 Clinical Application" page 744, right-hand column, line 4 - 17	17,20,21
X	----- US 5 279 298 A (FLOWER ROBERT W) 18 January 1994 (1994-01-18)	14,17,20
A	column 4, line 35 -column 5, line 10 column 6, line 3 - line 24 -----	21

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00274

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9846122	A	22-10-1998	AU 7063698 A EP 0975258 A	11-11-1998 02-02-2000
WO 9618415	A	20-06-1996	US 5935942 A AU 4110396 A CA 2207624 A EP 0799055 A JP 10510807 T	10-08-1999 03-07-1996 20-06-1996 08-10-1997 20-10-1998
US 5279298	A	18-01-1994	AU 5618494 A EP 0669819 A JP 8503406 T WO 9412092 A	22-06-1994 06-09-1995 16-04-1996 09-06-1994